Valuing Telemedicine GLP's Clinics: Opportunities in a Booming Market
The GLP's market could hit $80–200B globally by 2030. Clinics with strong telemedicine, 503A/503B partnerships, and patient retention are commanding high valuations. Here is what drives value.
Valuing Telemedicine GLP-1 Clinics: Opportunities in a Booming Market
The global GLP-1 market is projected to reach $80–200 billion by 2030, driven by the expanding indications for GLP-1 therapy (obesity, cardiovascular disease, kidney disease, sleep apnea, MASH) and the massive unmet need for effective obesity treatment. Within this market, telemedicine GLP-1 clinics occupy a uniquely attractive position — and private equity has noticed.
Why Telemedicine GLP-1 Clinics Are Attractive to Buyers
Scalability Without Physical Infrastructure
Traditional medical practices scale by adding physical locations — expensive, slow, and operationally complex. Telemedicine GLP-1 clinics scale by adding patients to a digital platform. The marginal cost of serving an additional patient is dramatically lower than in a brick-and-mortar practice.
This scalability is the primary reason PE buyers are willing to pay premium multiples for telemedicine-enabled GLP-1 clinics.
Recurring Revenue
GLP-1 therapy is a long-term treatment. Patients who start GLP-1 therapy typically continue for years — and most regain weight if they stop. This creates a recurring revenue stream that is highly predictable and valuable.
A practice with 500 patients on a $300/month GLP-1 program generates $150,000/month in recurring revenue. PE buyers pay premium multiples for this kind of predictable cash flow.
Large and Growing Market
The addressable market for GLP-1 therapy is enormous. Approximately 42% of U.S. adults are obese, and a significant proportion have comorbidities (T2D, cardiovascular disease, sleep apnea) that create additional clinical indications. The market is growing as awareness increases and access improves.
What Drives Valuation for Telemedicine GLP-1 Clinics
Recurring Revenue Percentage
The single most important valuation driver. Practices with 60%+ recurring revenue (monthly memberships, subscription programs) command significantly higher multiples than practices with primarily transactional revenue.
Target: Build recurring revenue to at least 50% of total revenue before going to market.
Patient Retention Metrics
PE buyers want to see:
- Monthly churn rate: Target <5% monthly churn
- Average patient duration: Target 12+ months
- Net revenue retention: Target >100% (expansion revenue from add-ons)
Document these metrics carefully — they are the first thing a sophisticated buyer will ask for.
Compliance Infrastructure
Telemedicine GLP-1 clinics that have invested in compliance infrastructure command premium multiples. This includes:
- Documented prescribing protocols
- Verified compounding supplier relationships (503A/503B)
- HIPAA-compliant telehealth platform
- State licensing in all states served
- Prescriber credentialing documentation
Compliance gaps are deal-killers or significant valuation discounts.
Diversification
Practices that have diversified beyond GLP-1 alone command higher multiples:
- NAD+ therapy: Natural add-on for GLP-1 patients
- RUO peptide research: IRB-supported research adds credibility and revenue
- Aesthetic services: For med spa-adjacent practices
- Metabolic health programs: Comprehensive programs beyond weight loss
Technology Infrastructure
Practices with proprietary or well-integrated technology (patient portal, automated monitoring, EHR integration) are more scalable and command higher multiples.
Typical Valuations in the Current Market
For established telemedicine GLP-1 clinics:
| Revenue Level | EBITDA Multiple | Approximate Valuation |
|---|---|---|
| $500k–$1M revenue | 4–6x EBITDA | $800k–$2M |
| $1M–$3M revenue | 5–7x EBITDA | $1.5M–$5M |
| $3M–$10M revenue | 6–9x EBITDA | $5M–$20M |
| $10M+ revenue | 8–12x EBITDA | $20M+ |
These are general ranges. Specific valuations depend on the factors discussed above.
Building for Value: The MedClinic Partners Advantage
MedClinic Partners was built by medical operators and mass-tort attorneys who understand both the clinical and business sides of GLP-1 programs. Our infrastructure — 503A portal, 503B supply, compliance support, IRB facilitation — is designed to help practices build the compliance and supply foundation that commands premium valuations.
If you are building a telemedicine GLP-1 clinic with an eye toward a future sale, the decisions you make now about supply chain, compliance, and revenue model will significantly affect your exit multiple.
This content is for informational purposes only and does not constitute legal or financial advice. Valuations vary significantly based on individual practice characteristics and market conditions.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
